CYP19A1 and breast carcinoma: Subgroup analyses of a phase 3 study showed that twice-yearly administration of denosumab consistently increased BMD (bone mineral density) versus placebo at 12 and 24 months for nonmetastatic breast cancer patients receiving adjuvant aromatase inhibitor therapy [10].